[ad_1]
The committee said in its guidelines: “The committee did not find sufficient evidence that remdesivir improved patient outcomes such as reduced mortality, reduced need for ventilation and reduced clinical improvement times, among other things.”
These guidelines represent another setback for the drug, which grabbed the world’s attention as a possible treatment for (Covid-19) in the summer after early studies showed some promising results.
At the end of October, Gilead lowered its revenue forecast for 2020, citing lower-than-expected demand and hard-to-predict remdesivir sales.
And that antiviral drug is currently one of only two drugs approved for use to treat patients with Covid-19 worldwide, but a large study conducted by the World Health Organization last month, known as the Solidarity Experience, showed that it had no effect or effect on mortality rates within 28 days of positive exams or hospital stay.
Remdesivir was one of the drugs doctors used to treat the President of the United States, Donald Trump, after he was infected with the Corona virus, and it has been shown in previous studies that it reduced recovery time and more than 50 countries have. approved as a treatment for Corona or authorized its use for this purpose.
Gilead Sciences questioned the results of the solidarity experiment.
“Vichlor has been recognized as the standard for inpatient care of hospitalized patients with Covid-19 in the guidelines of many leading national organizations,” he said in a statement, referring to the drug’s brand.
“We are disappointed that WHO guidelines ignore this evidence at a time when cases are increasing dramatically around the world and doctors are relying on PhyClure as the first antiviral treatment approved only for patients with Covid-19,” he added.
The WHO guideline development group said its recommendation was based on a review of the evidence that included data from 4 international randomized trials involving more than 7,000 hospitalized patients with COVID-19.
.
[ad_2]
Source link
